ELOY DEL
POTRO GÓMEZ
Investigador ata 2016
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (6)
2017
-
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols
Leukemia and Lymphoma, Vol. 58, Núm. 1, pp. 145-152
2014
-
Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols
Cancer, Vol. 120, Núm. 24, pp. 3958-3964
-
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial
Journal of Clinical Oncology, Vol. 32, Núm. 15, pp. 1595-1604
2010
-
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group
Haematologica, Vol. 95, Núm. 4, pp. 589-596
2005
-
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial
Haematologica, Vol. 90, Núm. 10, pp. 1346-1356
-
Prevalencia y significado pronóstico de los marcadores mieloides en adultos con leucemia aguda linfoblástica de alto riesgo
Medicina Clinica, Vol. 125, Núm. 7, pp. 241-246